Motley Fool
Long-term investing & stock picks
BioNTech Stock Recently Got Downgraded. But Is Wall Street Underestimating Its Cancer Pipeline?
By newsfeedback@fool.com (Keith Speights)
Read original article on Motley FoolBMO (NYSE: BMO) Capital Markets has been quite bullish about BioNTech SE (NASDAQ: BNTX) this year. However, that's no longer the case.
On Sept. 8, 2026, BioNTech's shares dipped after BMO downgraded the biotech stock from an "outperform" rating to a "market perform" rating. BMO also lowered its 12-month price target for BioNTech from $128 to $105.
There's a simple explanation for BMO's new take on BioNTech. But is Wall Street underestimating the company's cancer pipeline?
This story was originally published on Motley Fool. DennTech aggregates headlines from top crypto publications to keep traders informed.
Read full article on Motley Fool